-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A widely available and inexpensive type 2 diabetes drug held great promise for treating breast cancer, but according to new findings, it does not prevent or stop the spread of the most common disea.
The randomized, double-blind trial enrolled patients taking two daily pills of a placebo or the diabetes drug metform.
"The results tell us that metformin is ineffective against most common types of breast cancer and that the drug should be discontinued for these common types of breast cancer," said .
While the study found metformin to be ineffective against the most common type of breast cancer, .
For this subtype of breast cancer, the researchers found evidence that 5 years of metformin use may reduce mortali.
"Metformin is not beneficial for most common breast cancers, but in the case of HER2-positive breast cancer, our findings suggest that it may be beneficial," said .
Metformin belongs to the biguanide class of drugs used to treat high blood sugar or diabet.
The research results have been submitted for publicati.
